NCT02637466View on ClinicalTrials.gov

Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers

PHASE4WithdrawnINTERVENTIONAL

0

Timeline

Start Date

July 31, 2016

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2019

Conditions

Unipolar Major DepressionStage I, II or III Breast Cancer

Interventions

DRUG

Vortioxetine

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Takeda

INDUSTRY

lead

University of Miami

OTHER